In the past few years, cancer immunotherapy, such as new immune modulators of cytokines and blockers of cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1/programmed death-ligand 1, have emerged as safe and effective alternatives for the treatment of cancers that do not respond to classical treatments [25]. This evidence concerns the gene CTLA4 and cancer.